Baiyunshan: The subsidiary has obtained approval for the market application of toluenesulfonic acid sorafenib chemical raw materials.

Baiyunshan announcement: Baiyunshan Chemical Pharmaceutical Factory, a subsidiary, has received the "Chemical Raw Material Drug Market Authorization Notification" issued by the State Drug Administration for the p-toluenesulfonic acid sorafenib. The notification number is 2025YS00407, the acceptance number is CYHS2360970, and the chemical raw material drug registration standard number is YBY64902025. P-toluenesulfonic acid sorafenib is mainly used for first-line treatment of advanced liver cancer, treatment of advanced kidney cancer, and local advanced or metastatic thyroid cancer that is ineffective with radioactive iodine therapy. Baiyunshan Chemical Pharmaceutical Factory has invested a total of approximately 3.3655 million yuan in the development of p-toluenesulfonic acid sorafenib raw materials. This approval will help enrich the variety of anti-tumor products of Baiyunshan Chemical Pharmaceutical Factory and enhance the company's competitiveness in the anti-tumor market.